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Abstract 
Follistatin (FST) is a cysteine-rich autocrine glycoprotein and plays an important role in mammalian prenatal and 
postnatal development. FST binds to and inhibit myostatin (MSTN), a potent negative regulator of skeletal muscle 
growth, and FST abundance enhances muscle growth in animals via inhibition of MSTN activity. The objective of this 
study was to produce biologically active, four chicken FST-type proteins in an Escherichia coli expression system. Gib-
son assembly cloning method was used to insert the DNA fragments of four FST-type proteins, designated as FST288, 
NDFSD1/2, NDFSD1, and NDFSD1/1, into pMALc5x vector downstream of the maltose-binding protein (MBP) gene, 
and the plasmids containing the inserts were eventually transformed into Shuffle E. coli strain for protein expression. 
We observed a soluble expression of the four MBP-fused FST-type proteins, and the proteins could be easily purified 
by the combination of amylose and heparin resin affinity chromatography. MBP-fused FST-type proteins demon-
strated their affinity to anti-FST antibody. In an in vitro reporter gene assay to examine their potencies and selectivities 
to different ligands (MSTN, GDF11, and activin A), the four FST-type proteins (MBP-FST288, MBP-NDFSD1/2, MBP-
NDFSD1, and MBP-NDFSD1/1) showed different potency and selectivity against the three ligands from each other. 
Ligand selectivity of each FST-type proteins was similar to its counterpart FST-type protein of eukaryotic origin. In con-
clusion, we could produce four FST-type proteins having different ligand selectivity in E. coli, and the results imply that 
economic production of a large amount of FST-type proteins with different ligand selectivity is possible to examine 
their potential use in meat-producing animals.
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Introduction
Improving the efficiency of meat-animal production 
is crucial to a sustainable supply of quality proteins to 
humans with minimal environmental footprints. Mus-
cle growth efficiency is probably one of the main deter-
minants of meat production efficiency, and some studies 
indicate that enhancing skeletal muscle growth improves 
the efficiency of feed utilization (Bailey et al. 1966; Web-
ster 1977), resulting in improved efficiency of meat-
animal production. Technologies positively modulating 
muscle growth process would contribute to enhancing 
meat-production efficiency. Recent studies have shown 
that myostatin (MSTN), a member of the transforming 
growth factor-β superfamily (TGF-β), is the most potent 
negative regulator of skeletal muscle growth (Lee 2004), 
implying that suppression of MSTN activity would be a 
strategy to improve skeletal muscle growth. In lab ani-
mals, many studies have indeed demonstrated that skel-
etal muscle growth can be enhanced by suppressing 
MSTN activity (Joulia-Ekaza and Cabello 2007; Lee 2004; 
Rodgers and Garikipati 2008). It has also been shown 
that in-ovo suppression of MSTN activity via anti-MSTN 
antibodies significantly improves post-hatch skeletal 
muscle growth of broilers (Kim et al. 2006), demonstrat-
ing that inhibition of MSTN activity is a viable strategy to 
enhance muscle growth in meat-producing animals.
One of such molecules suppressing MSTN activity is 
follistatin (FST), a cysteine-rich autocrine glycoprotein 
that plays an important role in mammalian prenatal and 
postnatal development. FST was initially identified as 
an inhibitor of follicular stimulating hormone via bind-
ing to activin, thus thought that the biological activity of 
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FST was restricted to the reproductive system (Robert-
son et al. 1987; Ueno et al. 1987). Further investigations, 
however, revealed that FST binds to multiple members of 
the TGF-β superfamily, and that biological activities of 
this protein encompass multiple organ systems, includ-
ing bone, skeletal muscle, and liver (DePaolo et al. 1991; 
Phillips and de Kretser 1998). In chicken pectoral mus-
cle cell cultures, FST enhanced muscle cell development 
(Link and Nishi 1997). FST’s inhibition of MSTN bind-
ing to its receptors has been demonstrated in vitro (Lee 
and McPherron 2001), supporting that the enhance-
ment of muscle cell development by FST was prob-
ably due to FST’s suppression of MSTN. Subsequently, 
various studies have shown that the abundance of FST 
or FST fragment in muscle via transgenesis, injection 
of expression plasmid, or single administration of FST 
gene via adeno-associated virus delivery system signifi-
cantly increased skeletal muscle mass/strength (Gilson 
et al. 2009; Haidet et al. 2008; Kota et al. 2009; Lee and 
McPherron 2001; Nakatani et al. 2008). Interestingly, the 
muscle mass increase in transgenic mice overexpress-
ing FST was significantly greater than that in MSTN null 
mice (Lee and McPherron 2001), and recent results sug-
gest that enhancement of muscle growth by FST is not 
only via MSTN suppression but also involves activin-
dependent mechanisms (Gilson et  al. 2009; Lee 2007; 
Lee et  al. 2010). Transgenic rainbow trout overexpress-
ing FST exhibited dramatic muscularity (Medeiros et al. 
2009). These results together indicate that FST would be 
a potential agent to improve skeletal muscle growth in 
agricultural animals, as well as, to treat skeletal muscle 
atrophic disorders in humans.
In a previous study, we were successful in producing 
bioactive full sequence of chicken FST (FST315) in an 
E. coli system using maltose binding protein (MBP) as 
a fusion partner (Lee et al. 2014), illustrating the poten-
tial of economic production of FST for application in 
meat-producing animals. FST is a multi-domain protein 
consisting of 5 domains (Fig. 1a), and FST-type proteins 
containing different FST domains have differential ligand 
suppressing activities (Cash et  al. 2012; Nakatani et  al. 
2011; Schneyer et al. 2008; Sidis et al. 2006). The ligand 
selectivity of FST-type proteins is an important property 
for FST-type proteins to be used in animals for improv-
ing skeletal muscle growth with minimal undesirable side 
effects that may arise from FST’s interaction with other 
ligands other than MSTN. It was, thus, contended that 
producing different FST-type proteins in an E. coli system 
and determining their bioactivities and ligand selectivity 
would contribute to examining their potentials in meat 
animal production. Therefore, the objective of this study 
was to produce biologically active, four different chicken 
FST288 5'-gggatcgagggaaggGGGAACTGCTGGCTCCGG-3'                             (forward) 
 5'-catggacatatgtgaaatTTAGTTGCAAGATCCAGAGTGCTTTAC-3'  (reverse) 
NDFSD1/2 5'-gggatcgagggaaggGGTAACTGCTGGCTGCGT-3'                              
(forward) 
 5'-catggacatatgtgaaatTTAAATGCATTTGCCTTCGTACG-3'                  
(reverse) 
NDFSD1 5'-gggatcgagggaaggGGTAACTGCTGGCTGCGT-3'                              
(forward) 
 5'-catggacatatgtgaaatTTACTTGCATTTGCCTTGGTAC-3'  (reverse) 
NDFSD1/1 5'-gggatcgagggaaggGGTAACTGCTGGCTGCGT-3'  (NDFSD1 forward) 
  5'-tcagagccgccgccCTTGCATTTGCCTTGGTACTG-3'  (NDFSD1 reverse) 
 5'-aaatgcaagggcggcggctctGAAACCTGCGAAAACGTC-3'  (FSD1 forward) 
                   5'-catggacatatgtgaaatttaCTTGCATTTGCCTTGGTAC-3’  (FSD1 reverse) 
a
b
Fig. 1 Different FST-type proteins (a) and Gibson assembly primer sets for four different FST-types (b). The sequences in small capital indicate over-
lap sequence part and the sequences in all capital indicate primer sequence part used for Gibson assembly cloning
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FST-type proteins in an E. coli expression system. Results 
of this study show that bioactive, four FST-type proteins 
can be produced in an E. coli system, and their ligand 
selectivity is different from each other, but the ligand 
selectivity of each FST-type protein is similar to its coun-
terpart FST-type protein of eukaryotic cell origin.
Materials and methods
Cloning of four FST‑type proteins into an expression vector 
and transformation of expression vectors
Since we previously used pMALc5x vector (New England 
Biolabs, MA, USA) in cloning for expression of bioactive 
chicken FST315 in an E. coli system (Lee et al. 2014), the 
same system was used in cloning four different FST-type 
proteins. The four FST-type proteins included FST288, 
NDFSD1/2, NDFSD1/1, and NDFSD1 (Fig.  1a). Gibson 
assembly cloning method (Gibson et al. 2009) was used 
to insert the DNA fragments of four FST-type proteins 
into pMALc5x vector separately. Gibson assembly prim-
ers for FST288 (GenBank Accession No. KT336491), 
NDFSD1/2 (GenBank Accession No. 336492), NDFSD1/1 
(GenBank Accession No. 336493), and NDFSD1 (Gen-
Bank Accession No. 336494) fragments were synthesized 
(Fig.  1b), and inserts were prepared by PCR amplifica-
tion using the Q5 High-Fidelity PCR kit (New England 
Biolabs) and chicken FST315 cDNA (Lee et al. 2014) as 
a template. PCR products were separated by agarose gel 
electrophoresis, and fragments were excised and purified 
before use in DNA assembly reaction with XmnI-line-
arized pMALc5x vector using Gibson Assembly® Clon-
ing kit (New England Biolabs). Each assembly reaction 
contained approximately 100  ng of insert and 50  ng of 
the expression vector and incubated at 50 °C for 30 min 
following the manufacturer’s protocol. After the assem-
bly reaction, the reaction mix was transformed into NEB 
5-alpha competent E. coli strain (New England Biolabs). 
After an overnight growth at 37 °C, the pMAL-c5x plas-
mids containing respective inserts were extracted using 
a plasmid extraction miniprep kit (Promega) to confirm 
correct insertion by colony PCR.
Cytoplasmic expression of four FST‑type proteins
Shuffle E. coli (New England Biolabs) were trans-
formed with pMALc5x-FST288, pMALc5x-NDFSD1/2, 
pMALc5x-NDFSD1, and pMALc5x-NDFSD1/1 plas-
mids. After confirmation of correct insertion by colony 
PCR, 5  mL Luria–Bertani (LB) (1.2  % tryptone, 0.6  % 
yeast extract and 0.8 % NaCl) medium containing 100 μg/
mL ampicillin and 0.2  % glucose were inoculated indi-
vidually with the Shuffle E. coli harboring the inserts, and 
grown overnight at 30  °C with vigorous shaking. Then, 
5  mL of the overnight cultures were transferred into 
1 L fresh LB medium containing ampicillin in 2 L flask. 
When the culture reached to an optical density of 0.3–
0.4 Å (600 nm) at 30 °C, the cultures were transferred to 
4 °C for protein expression induced by adding Isopropyl 
β-d-1-thiogalactopyranoside (IPTG) to a final concentra-
tion of 0.4 mM under vigorous shaking. After induction 
for 8  days, E.coli pellet was harvested by centrifugation 
at 4000g for 10  min at 4  °C. Each gram (wet weight) of 
the cell pellet was resuspended in 5 mL of affinity column 
buffer (20  mM Tris–Hcl, 200  mM NaCl, 1  mM EDTA, 
pH 7.4) containing the Complete Mini Protease Inhibi-
tor cocktail tablet (Roche, Mannheim, Germany). Two 
microliter of lysozyme (50  μg/mL) and 2  μL of DNase 
I (2500 units/ml) were added per 1  mL column buffer. 
The resuspended cell solution was lysed by sonication in 
short pulses of 15 s for 10 min in ice water bath. The solu-
ble and insoluble fractions were prepared by centrifuga-
tion at 10,000g for 20 min at 4  °C. For each sample, the 
supernatants (soluble fraction) were collected, and the 
same volume of column buffer was used to resuspend the 
pellets (insoluble fraction). Total, soluble and pellet frac-
tions were analyzed by SDS-PAGE to examine the pres-
ence of MBP-fused recombinant proteins (MBP-FST288, 
MBP-NDFSD1/2, MBP-NDFSD1, and MBP-NDFSD1/1).
Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS‑PAGE)
SDS-PAGE was performed with gels containing l2.5  % 
polyacrylamide and 0.1  % SDS following the procedure 
of Laemmli (1970). Samples were mixed with 3X load-
ing buffer which were under reducing conditions. Before 
loading the sample onto the SDS-PAGE gel, samples were 
boiled at 100 °C for 5 min.
Amylase affinity purification of MBP‑fused FST‑type 
proteins
Supernatant cell extracts were diluted with affinity col-
umn buffer in a 1:5 ratio, and filtered through 0.45 μm 
filter, then was loaded into an amylose resin column 
equilibrated with 100  mL of column buffer. After load-
ing, the pass-through was collected at a rate of 0.5  ml/
min and washed with 100  mL of column buffer. Pro-
teins bound to the column were then eluted with elution 
buffer (column buffer with 10 mM maltose) at a flow rate 
of 0.5 ml/min. 5 mL fractions were collected during elu-
tion, and the absorbance was monitored at 280 nm. After 
SDS-PAGE analysis of the presence of recombinant pro-
tein in fractions, fractions containing recombinant pro-
teins were pooled.
Heparin affinity purification of MBP‑fused FST‑type 
proteins
For further purification of amylose affinity-purified MBP-
fused proteins, the pooled elutions were subjected to 
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heparin affinity column (Bio-Rad, CA, USA) previously 
equilibrated with column buffer. The pass-through was 
collected at a rate of 1  ml/min. The column was then 
washed with 100 mL of column buffer. Proteins bound to 
the column were then eluted with elution buffer (column 
buffer with 1 M NaCl). After SDS-PAGE analysis of the 
presence of recombinant protein in fractions, fractions 
containing recombinant proteins were pooled, followed 
by dialysis in phosphate buffered saline solution.
Western‑blot analysis
Affinity-purified MBP-fused proteins were subjected to a 
12.5 % SDS-PAGE, followed by a transfer onto a polyvi-
nylidene fluoride (PVDF) membrane. The membrane was 
blocked for 1 h at room temperature with 5 % non-fat dry 
milk in Tris-buffered saline with 0.1 % Tween-20 (TTBS). 
The membranes was incubated with the goat anti-FST 
(1:5,000 in TTBS, R&D Systems, MN, USA) overnight 
at 4  °C. The membrane was then washed three times 
(10  min for each wash) with TTBS, followed by incu-
bation with 1:10,000 alkaline phosphatase-conjugated 
anti-goat IgG (Sigma, MO, USA) in TTBS for 1 h. After 
washing, the membrane was developed using BCIP/
NBT substrate (nitrobluetetrazolium and bromo-chloro-
indolyl phosphate from Sigma).
Bioactivity test of MBP‑fused FST‑type proteins 
by pGL3‑(CAGA)12 Luc‑luciferase reporter system
The capacities of MBP-FST288, MBP-NDFSD1/2, MBP-
NDFSD1, and MBP-NDFSD1/1 to suppress the bioactiv-
ity of three FST-binding proteins (MSTN, GDF11, and 
activin A, all from R&D Systems) were examined by a 
procedure that was used in examining the bioactivity 
of MBP-fused chicken FST315 (Lee et  al. 2014). Briefly, 
cells stably transformed with pGL3-(CAGA)12 luciferase 
reporter construct (Cash et al. 2012) were seeded in a 96 
well plate for 24 h at 37  °C with 5 % CO2. The medium 
was replaced with 100 μL serum-free DMEM contain-
ing 1 nM MSTN, GDF11 or activin A plus various con-
centrations of FST-type proteins, then incubated for 
24  h. After removing the medium, Bright-Glo lumines-
cence substrate (Promega) was added, and luminescence 
was measured. The   % inhibition of MSTN, GDF11 or 
activin A activity was calculated by the following for-
mula: % inhibition  =  (luminescence at 1  nM MSTN, 
GDF11 or activin A-luminescence at each ligand con-
centration) × 100/(luminescence at 1 nM MSTN, GDF11 
or activin A-luminescence at 0  nM MSTN, GDF11 or 
activin A). The MSTN-, GDF11- or activin A-inhibitory 
activity was analyzed by regression analysis using Prism 
5 program (Graphpad, CA, USA). To examine the dif-
ferences in MSTN-, GDF11- or activin A-inhibitory 
capacity of these proteins, IC50 (ligand concentration 
inhibiting 50  % of MSTN, GDF11 or activin A activ-
ity) values were estimated using a non-linear regression 
model defining dose response curve. The equation for 
the model was as follows: Y: Bottom + (Top − Bottom)/
[1  +  10^(X  −  LoglC50)], where Y is % inhibition, Bot-
tom is the lowest value of % inhibition, Top is the highest 
value of % inhibition, and X is Log ligand concentration 
IC50 values were analyzed by ANOVA (Analysis of Vari-
ance) using the same program.
Results
Cytoplasmic expression of MBP‑fused FST‑type proteins 
in Shuffle E. coli system
In our previous study (Lee et al. 2014), we observed that 
induction at 4  °C for 8  days resulted in a higher yield 
of affinity-purified, MBP-fused chicken FST315 than 
8  h induction at 25  °C even though the yield of solu-
ble forms of the recombinant protein was much higher 
at 25  °C induction, probably due to an improvement in 
proper folding at lower temperature. Thus, we expressed 
four FST-type proteins (MBP-FST288, MBP-NDFSD1/2, 
MBP-NDFSD1, and MBP-NDFSD1/1) at 4 °C for 8 days, 
and purified the proteins. Like the MBP-fused chicken 
FST315, all four FST-type proteins were expressed in a 
soluble form (Data not shown). When soluble fractions 
of these proteins were purified using a combination of 
amylose and heparin affinity chromatography, the purifi-
cation appeared to be more than 90 %, and the locations 
of each form of FST in reduced SDS-PAGE gel were at 
the expected size (Fig. 2a). Western blot analysis showed 
that the four FST-type proteins had affinity to anti-FST 
antibody (Fig.  2b), confirming the identity of each pro-
teins. When the proteins were subjected to SDS-PAGE in 
non-reduced condition (Fig. 2c), presence of some aggre-
gates was observed in all four FST-type proteins with 
almost equal proportion at around 50 %.
The yield of amylose/heparin affinity-purified MBP-
FST288, MBP-NDFSD1/2, MBP-NDFSD1/1, and MBP-
NDFSD1 were 7.5, 15.8, 14.5 and 19.8  mg/L culture, 
respectively (Table  1). In our previous study, the yield 
of amylose/heparin affinity purified MBP-FST315 was 
5.8 mg/L culture (Lee et al. 2014). It, thus, appears that 
the yield of MBP-fused FST-type protein is negatively 
related to the size of molecules.
Bioactivity of MBP‑fused FST‑type proteins
The abilities of MBP-FST288, MBP-NDFSD1/2, MBP-
NDFSD1, and MBP-NDFSD1/1 to suppress MSTN, 
GDF11, and activin A were examined using pGL3-
(CAGA)12 Luc-luciferase reporter assay (Fig. 3), and their 
potencies were compared each other, as well as to com-
mercial recombinant human FST produced in eukaryotic 
cells (rhFST315/CHO, R&D Systems) or to MBP-FST315. 
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It has been observed in our previous study that the pres-
ence of MBP as a fusion partner had no influence on the 
MSTN- or activin A-inhibitory capacity of FST315 (Lee 
et al. 2014). The removal of aggregates appeared in non-
reduced condition of SDS-PAGE by gel-filtration did not 
significantly affect the MSTN- or activin A-inhibitory 
capacity of FST315 (Lee et al. 2014). Therefore, in meas-
uring the bioactivities of FST-type proteins, we used 
amylose/heparin affinity-purified proteins without fur-
ther purification.
Fig. 2 SDS-PAGE and Western blot analysis of four FST-type proteins containing MBP as a fusion partner. Purified protein samples were subjected 
to 12.5 % SDS-PAGE either in reduced (a) or non-reduced (c) conditions and stained with Coomassie blue. Proteins fractionated by SDS-PAGE were 
transferred onto polyvinylidene fluoride (PVDF) membrane electrophoretically, followed by immunoblotting against polyclonal anti-human FST 
(1:200) antibodies (b). Lanes 1, 2, 3 and 4 indicate MBP-NDFSD1, MBP-NDFSD1/2, MBP-NDFSD1/1, and MBP-FST288, respectively
Table 1 Yields of  various FST-type proteins after  com-
bined affinity purification of amylose and heparin resins
Protein concentration was measured by Lowry method using BSA as a standard. 
The protein recovery was calculated as the mean ± SEM from purifications of a 






Fig. 3 Inhibition of MSTN, GDF11 or activin A activities by various FST-type proteins. HEK293 cells stably expressing (CAGA)12-luciferase gene con-
struct were seeded on a 96-well culture, and grown for 24 h in DMEM with 10 % fetal calf serum, antibiotic and antimycotic. Medium was removed, 
and MSTN (1 nM), GDF11 (1 nM) or activin A (1 nM) plus various concentrations (180–0 nM) of FST-type proteins in DMEM were added to each well, 
followed by incubation for 24 h. Medium was removed, and luminescence substrate was added, followed by luminescence measurement. The error 
bars represent ± SEM (n = 6)
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Figure 3a shows the inhibition of 1 nM MSTN by dif-
ferent forms of MBP-fused FST. The IC50 values of 
MBP-FST288, MBP-NDFSD1/2, MBP-NDFSD1, and 
MBP-NDFSD1/1 to suppress MSTN were 2.01, 10.47, 
68.93, and 63.97 nM, respectively, and these values were 
significantly different from each other except the val-
ues between MBP-NDFSD1 and MBP-NDFSD1/1. The 
IC50 values of these proteins for suppression of MSTN 
were significantly higher than that of rhFST315/CHO 
(0.52 nM). The IC50 value of MBP-FST288 (2.01 nM) for 
suppression of MSTN was significantly lower than that of 
MBP-FST315 (4.81 nM).
Figure  3b shows the inhibition of 1  nM GDF11 by 
different FST-type proteins. The IC50 values of MBP-
FST288, MBP-NDFSD1/2, MBP-NDFSD1, and MBP-
NDFSD1/1 to suppress GDF11 were 1.64, 3.56, 57.88, 
and 26.22 nM, respectively, and these values were signifi-
cantly different from each other. The IC50 values of these 
proteins for suppression of GDF11 were significantly 
higher than that of rhFST315/CHO (0.52  nM). MBP-
FST288 had lower IC50 value than MBP-FST315 (1.64 vs 
6.35 nM).
Figure  3c shows the result of the inhibition of 1  nM 
activin A by different FST-type proteins. The IC50 values 
of MBP-FST288, MBP-NDFSD1/2, and MBP-NDFSD1 to 
suppress activin A were 3.96, 8.59 and 15.30 nM, respec-
tively. MBP-NDFSD1/1 did not show its capacity to sup-
press activin A activity. The IC50 value of rhFST315/CHO 
(0.40  nM) was significantly lower than those of MBP-
fused FST-type proteins.
Discussion
FST is a multi-domain glycoprotein consisting of 5 
domains, including N-terminal domain followed by three 
FST domains (FSD1-3) and C-terminal domain (Shima-
saki et al. 1988). Three isoforms of FST, including FST315, 
FST303, and FST288, have been identified in vivo (Sch-
neyer et al. 2004). FST315 encompasses all domains, and 
FST288 is lacking the C-terminal domain, and FST303 
arises from proteolytic cleavage of the FST315 C-termi-
nal tail (Sugino et al. 1993). These isoforms have shown 
locational compartmentalization and different biological 
roles in  vivo (Kimura et  al. 2010; Schneyer et  al. 2004). 
Studies, which analyzed the importance of the different 
domains and domain arrangement of FST-type proteins 
on ligand binding, have shown that FST-derived pep-
tides containing different FST domains have differential 
MSTN, activin and GDF11 suppressing activities (Cash 
et  al. 2012; Nakatani et  al. 2011; Schneyer et  al. 2008; 
Sidis et al. 2006), illustrating the potential to obtain selec-
tive antagonists against a specific ligand. The different 
FST-type proteins used in those studies were all eukar-
yotic origin. As compared to E. coli systems, the use of 
eukaryotic system is in general more costly in producing 
recombinant proteins, limiting research with the recom-
binant proteins on meat-producing animals. Recently, we 
expressed bioactive chicken FST315 in a soluble form in 
E. coli using MBP as a fusion partner (Lee et  al. 2014), 
and in this study, we were also able to produce bioac-
tive four chicken MBP-fused FST-type proteins, includ-
ing MBP-FST288, MBP-NDFSD1/2, MBP-NDFSD1, and 
MBP-ND-FSD1/1. Our results also showed that the pro-
duction yield increases with the decrease in the size of 
FST-type proteins.
We examined the capacities of these four FST-type 
proteins to suppress the activities of MSTN, GDF11, 
and activin A, which share a common core of signaling 
components, including type I and type II activin recep-
tors and Smad2 and 3 phosphorylation. In our previous 
study (Lee et al., 2014), we observed that the potency of 
chicken MBP-FST315 to suppress MSTN or activin was 
lower than mammalian-derived human FST, and cleavage 
of MBP from MBP-FST315 did not change the potency, 
indicating that MBP fusion does not affect MBP-fused 
FST bioactivity. It is, thus, possible that the lower 
potency of MBP fused chicken FST315 compared to 
mammalian-derived human FST was due to a sequence 
difference between chicken and human FST. Since MBP 
fusion showed no effect on FST bioactivity, the bioac-
tivities of four FST-type proteins were examined without 
MBP removal.
The examination of the capacity of these FST-type pro-
teins to suppress three different ligands (MSTN, GDF11, 
and activin A) revealed that their ligand selectivity is dif-
ferent from each other. The IC50 values of MBP-FST288 
to suppress MSTN, GDF11, and activin A were signifi-
cantly lower than those of MBP-FST315, indicating that 
MBP-FST288 is more potent in suppressing the three 
ligands than MBP-FST315. This result is in agreement 
with previous studies, in which FST288 of eukaryotic ori-
gin had a higher affinity or inhibitory potency for vari-
ous ligands compared with FST315 of eukaryotic origin 
(Hashimoto et  al. 2000; Inouye et  al. 1991; Sidis et  al. 
2006; Sugino et  al. 1993). It is, thus, indicated that the 
N-terminal presence of MBP in FST288 did not have 
much influence on the interaction of this molecule with 
the three ligands.
The potencies of MBP-NDFSD1/2 to suppress MSTN, 
GDF11 and activin A were two-five fold lower compared 
with MBP-FST288, indicating that the FSD3 of FST con-
tribute to the binding of FST to its ligands. In support of 
the result, Cash et al. (2012) recently reported that FSD3 
provides affinity to ligand and stability on perturbations 
in the ND and FSD2 probably through the interaction 
of FSD3 of one FST molecule with the ND of the other 
FST molecule. It is generally regarded that a continuous 
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sequence comprising ND followed by FSD1 and 2 is 
essential for activin binding and bioactivity (Keutmann 
et al. 2004). The crystal structure of FST288:activin com-
plex has shown that the type II receptor binding site 
is blocked by both FSD1 and FSD2 (Thompson et  al. 
2005). Results by Schneyer et  al. (2008) showed that 
activin binding and neutralization are mediated primar-
ily by FDS2, whereas MSTN binding is more dependent 
on FSD1, such that deletion of FSD2 or adding an extra 
FSD1 in place of FSD2 create MSTN antagonists with 
vastly reduced activin antagonism. In support of the cru-
cial role of FSD2 for activin inhibition, Keutmann et  al. 
(2004) reported that eukaryotic cell-originated FST com-
prising only ND plus FSD1 had no biological activity at 
a dose 1000 fold higher than that eliciting a significant 
activity from FST288. In the current study, the potency 
of MBP-NDFSD1 to suppress the above three ligands 
significantly lower than MBP-FST315, MBP-FST288, or 
MBP-NDFSD1/2, supporting the role of FSD2 in ligand 
binding. However, in contrast to the result of Keutmann 
et al. (2004) and Schneyer et al. (2008), our result shows 
that the presence of FSD2 is more crucial for inhibition of 
MSTN or GDF11 than the inhibition of activin A because 
the potency decreases of MSTN and GDF11 from MBP-
NDFSD1/2 to MBP-NDFSD1 were about 6 fold and 15 
fold, respectively, while the decrease was only 2-fold for 
activin A. Given that the FST-type proteins used in this 
study contained MBP as a fusion partner with no gly-
cosylation due to its E. coli origin, it is speculated that 
either the presence of MBP and/or lack of glycosylation 
potentially affected the interaction between FSD1 and 
activin A, MSTN or GDF11.
It has been recently reported that FST-NDFSD1/1 
had an affinity for MSTN, but not for activin A (Cash 
et  al. 2012; Nakatani et  al. 2008; Schneyer et  al. 2008), 
indicating that NDFST1/1 have a potential as an agent 
to improve muscle growth via specific MSTN inhibi-
tion with minimal effect on activin activity. Like the 
NDFSD1/1 of eukaryotic origin, the MBP-NDFSD1/1 
showed that it did not inhibit activin A activity, but 
inhibited MSTN activity with similar potency to MBP-
NDFSD1. MBP-NDFSD1/1 also suppressed the GDF11 
activity. In agreement with this result, the NDFSD1/1 of 
eukaryotic origin has also shown to inhibit GDF11 (Sch-
neyer et  al. 2008). Interestingly, the potency of MBP-
NDFSD1/1 to suppress GDF11 was almost 2.5 fold higher 
compared with MBP-NDFSD1. The results together indi-
cate that MBP-NDFSD1/1 can suppress MSTN activ-
ity without much effect on activin, but it can suppress 
GDF11 activity, thus potential side effects arising from 
GDF11 inhibition by NDFSD1/1 need to be considered 
in using NDFSD1/1 as an agent to improve skeletal mus-
cle growth via MSTN inhibition. Furthermore, FST315 
and FST288 have been shown to bind to other TGF-beta 
superfamily member proteins, such as BMP-6 and MBP-7 
(Sidis et al. 2006), and current study did not examine the 
binding of FST-type proteins to other TGB-beta super-
family member proteins. Thus, the binding of FST type 
proteins to other TGF-beta superfamily member proteins 
also needs to be examined before consideration of these 
proteins for an agent to improve skeletal muscle growth 
or for other therapeutic potentials. In summary, the cur-
rent study demonstrated that bioactive chicken FST-type 
proteins can be produced in an E. coli system. Current 
results also show that the ligand selectivity of four dif-
ferent FST-type proteins is different from each other, but 
the ligand selectivity of each FST-type protein is similar 
to its counterpart FST-type protein of eukaryotic origin.
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